Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries
- PMID: 19564562
- DOI: 10.1161/CIRCULATIONAHA.107.730010
Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries
Abstract
Background: Although both sirolimus (CYPHER) and paclitaxel (TAXUS) drug-eluting stents have demonstrated efficacy and safety in clinical trials, human autopsy data have raised concerns about long-term healing and the potential for local inflammatory reactions.
Methods and results: Overlapping stents (CYPHER drug-eluting stents, Bx SONIC bare metal stents, TAXUS drug-eluting stents, and Liberté bare metal stents) were implanted in noninjured coronary arteries of 58 domestic swine. Histopathological evaluation of proximal, overlapped, and distal stented segments was determined with emphasis on inflammation at 30, 90, and 180 days. Circumferential granulomatous inflammation in all stented segments was defined as inflammation consisting of macrophages, multinucleated giant cells, lymphocytes, and granulocytes, including many eosinophils, adjacent to almost all struts. Circumferential granulomatous inflammation was more prevalent in CYPHER (9 of 23, 39%) compared with TAXUS (1 of 21, 5%; P=0.01) and control bare metal stents (0 of 44) in the combined 90- and 180-day cohorts. Only CYPHER specimens showed marked adventitial inflammation (P=0.0025) and fibrosis (P=0.0055) accompanied by extensive remodeling. Fibrin deposition within neointima and medial smooth muscle cell death were greater (both P<0.001) in TAXUS than CYPHER at 30 days, with more fibrin in TAXUS than CYPHER through 90 days (P<0.05).
Conclusions: Although these data cannot be directly extrapolated to humans, the high prevalence in this porcine model of diffuse granulomatous inflammation seen with CYPHER stents, persisting at 180 days and associated with extensive remodeling of the artery, and persistent para-strut fibrin deposition with TAXUS stents emphasize the need for further investigation of biocompatibility with these and other novel combination drug/polymer drug-eluting stents.
Comment in
-
Drug-eluting stents in animals and patients: where do we stand today?Circulation. 2009 Jul 14;120(2):101-3. doi: 10.1161/CIRCULATIONAHA.109.872473. Epub 2009 Jun 29. Circulation. 2009. PMID: 19564555 No abstract available.
Similar articles
-
Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.Circulation. 2005 Jul 12;112(2):270-8. doi: 10.1161/CIRCULATIONAHA.104.508937. Epub 2005 Jul 5. Circulation. 2005. PMID: 15998681
-
Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model.Cardiovasc Res. 2007 Nov 1;76(2):361-72. doi: 10.1016/j.cardiores.2007.07.004. Epub 2007 Jul 18. Cardiovasc Res. 2007. PMID: 17716637
-
Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model.Circ Cardiovasc Interv. 2010 Apr;3(2):174-83. doi: 10.1161/CIRCINTERVENTIONS.109.877522. Circ Cardiovasc Interv. 2010. PMID: 20407114
-
The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents.Am J Cardiol. 2007 Oct 22;100(8B):36M-44M. doi: 10.1016/j.amjcard.2007.08.020. Am J Cardiol. 2007. PMID: 17950831 Review.
-
Cypher versus taxus: are there differences?J Interv Cardiol. 2005 Dec;18(6):441-6. doi: 10.1111/j.1540-8183.2005.00084.x. J Interv Cardiol. 2005. PMID: 16336424 Review.
Cited by
-
Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.J Clin Med. 2021 Mar 19;10(6):1278. doi: 10.3390/jcm10061278. J Clin Med. 2021. PMID: 33808678 Free PMC article.
-
Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR.PPAR Res. 2016;2016:7407153. doi: 10.1155/2016/7407153. Epub 2016 Jun 14. PPAR Res. 2016. PMID: 27403152 Free PMC article.
-
Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium.Eur Heart J. 2016 May 14;37(19):1538-49. doi: 10.1093/eurheartj/ehv419. Epub 2015 Aug 30. Eur Heart J. 2016. PMID: 26761950 Free PMC article.
-
Viral-derived Serp-1 as an adjunctive therapy for percutaneous coronary intervention: another not ready for prime time player?Circ Cardiovasc Interv. 2010 Dec;3(6):528-30. doi: 10.1161/CIRCINTERVENTIONS.110.959684. Circ Cardiovasc Interv. 2010. PMID: 21156927 Free PMC article. No abstract available.
-
Low-dose sirolimus-eluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo.J Thromb Thrombolysis. 2012 Jul;34(1):91-8. doi: 10.1007/s11239-012-0696-8. J Thromb Thrombolysis. 2012. PMID: 22350685 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources